N/A N=93 Impact of E-cigarette Characteristics on Reinforcement and Tobacco Use Patterns
Smoking · Tobacco Use
Primary: Mean Cigarettes Per Day — 13.1; 12.6; 12.2; 13.3 cigarettes per day
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=49 Surgery and/or Radiation Therapy or Standard Therapy and/or Clinical Observation in Treating Patients With Previously Treated Stage IV Non-small Cell Lung Cancer
Recurrent Lung Non-Small Cell Carcinoma · Stage IV Non-Small Cell Lung Cancer AJCC v7
Primary: Progression-free Survival (PFS) — 14.2; 4.4 Months
N/A N=377 Impact of Modifiable Psychosocial Factors on Veterans' Long-term Trajectories of Functioning and Quality of Life
PTSD · Depression · Chronic Pain
Primary: Columbia Suicide Scale — 1.19; 1.09 score on a scale
Phase 2 N=43 Atezolizumab in Combination With Bevacizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma
Melanoma
Primary: Objective Response Rate (ORR) in the Full Analysis Set Analysis Population — 45.0 Percentage of participants
Phase 2 N=15 Nivolumab in AML in Remission at High Risk for Relapse
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome · Adult Acute Myeloid Leukemia in Remission · Blasts Under 10 Percent of Bone Marrow Nucleated Cells
Primary: Recurrence-free Survival Rate — 8.5 Months
Phase 2 N=4 Sirolimus and Familial Adenomatous Polyposis (FAP)
Adenomatous Polyposis Coli
Primary: Change in Marked Polyp Size — 16; 4; 0 Size of marked polyps
Phase 2 N=20 Safety, Tolerability, and Efficacy of Saroglitazar Mg 4 mg in Liver Transplant Recipients With Nonalcoholic Fatty Liver Disease (NAFLD)
Liver Transplant; Complications · NAFLD
Primary: Number of Participants With Adverse Events Assessed by CTCAE — 12 Participants
Phase 3 N=91 A Study of the Efficacy, Safety and Tolerability of Chronocort in Treating CAH
Congenital Adrenal Hyperplasia
Primary: Safety and Tolerability - Number of Participants With Adrenal Insufficiency — 25; 41 Participants
Phase 3 N=400 A Study to Learn About the Safety and Immune Response of 20vPnC in Adults in India.
Pneumococcal Disease
Primary: Percentage of Participants With Local Reactions Within 7 Days After Vaccination — 1.0; 1.0; 0.0; 0.5 Percentage of participants
Phase 2 N=258 The Anchor Study: Digitally Delivered Intervention for Reducing Problematic Substance Use
Alcohol Use Disorder (AUD) · Substance Use Disorders
Primary: Change in Number of Substance Use Occasions — -11.3; -11.2; -13.6; -12.9 occasions
Phase 2 N=106 Saroglitazar Magnesium in Patients With Nonalcoholic Fatty Liver Disease and/or Nonalcoholic Steatohepatitis
Non-Alcoholic Fatty Liver Disease · Nonalcoholic Steatohepatitis
Primary: Percentage Change From Baseline in Serum Alanine Aminotransferase (ALT) Levels at Week 16 — -26.2; -27.0; -44.9; 2.6 Percentage change — p=0.0002
Phase 3 N=546 Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery
Pancreatic Adenocarcinoma · Pancreatic Ductal Adenocarcinoma · Pancreatic Intraductal Papillary-Mucinous Neoplasm
Primary: Overall Survival (Percentage of Participants Alive) [Phase II] — 29.9; 28.1 months — p=0.62
Phase 4 N=834 Early Administration of Steroids in the Ambulance Setting
Asthma in Children
Primary: Hospital Admission — 57; 208 Participants
Phase 3 N=473 Comparative Efficacy and Safety Study of RGB-14-P and Prolia® in Women With Postmenopausal Osteoporosis
Postmenopausal Osteoporosis
Primary: Percentage Change From Baseline (%CfB) in Lumbar Spine Bone Mineral Density (BMD) — 5.68; 5.19 Percentage change from baseline
Phase 1 N=9 Study of Proton Therapy in Adjuvant Pancreatic Cancer
Resected Pancreatic Adenocarcinoma
Primary: Incidence of Dose Limiting Toxicites (DLTs) — 0; 1 Dose limiting Toxicities